IXJ Stock Overview
iShares Trust - iShares Global Healthcare ETF is an exchange traded fund launched by BlackRock, Inc.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
iShares Trust - iShares Global Healthcare ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.64 |
| 52 Week High | US$93.37 |
| 52 Week Low | US$77.96 |
| Beta | 0.65 |
| 1 Month Change | -4.43% |
| 3 Month Change | -0.68% |
| 1 Year Change | 1.28% |
| 3 Year Change | 8.02% |
| 5 Year Change | 50.45% |
| Change since IPO | 244.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| IXJ | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | -2.1% | -2.6% | -3.7% |
| 1Y | 1.3% | 22.7% | 20.5% |
Return vs Industry: IXJ underperformed the US Capital Markets industry which returned 22.2% over the past year.
Return vs Market: IXJ underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| IXJ volatility | |
|---|---|
| IXJ Average Weekly Movement | 1.4% |
| Capital Markets Industry Average Movement | 3.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IXJ has not had significant price volatility in the past 3 months.
Volatility Over Time: IXJ's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | n/a | www.ishares.com/us/products/239744/ishares-global-healthcare-etf |
iShares Trust - iShares Global Healthcare ETF is an exchange traded fund launched by BlackRock, Inc. It is managed by BlackRock Fund Advisors. It invests in public equity markets of global region. It invests in stocks of companies operating across health care sectors.
iShares Trust - iShares Global Healthcare ETF Fundamentals Summary
| IXJ fundamental statistics | |
|---|---|
| Market cap | US$4.19b |
| Earnings (TTM) | US$374.92m |
| Revenue (TTM) | US$71.70m |
11.2x
P/E Ratio58.5x
P/S RatioIs IXJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXJ income statement (TTM) | |
|---|---|
| Revenue | US$71.70m |
| Cost of Revenue | US$0 |
| Gross Profit | US$71.70m |
| Other Expenses | -US$303.22m |
| Earnings | US$374.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | 522.93% |
| Debt/Equity Ratio | 1.3% |
How did IXJ perform over the long term?
See historical performance and comparison